InflaRx N.V. (IFRX)
NASDAQ: IFRX · Real-Time Price · USD
2.090
+0.040 (1.95%)
Sep 11, 2026, 4:00 PM EDT - Market closed
InflaRx Market Cap
InflaRx has a market cap or net worth of $308 million as of September 11, 2026. Its market cap has increased by 187.74% in one year.
Market Cap
308.00M
Enterprise Value
127.85M
1-Year Change
187.74%
Ranking
Category
Stock Price
$2.09
ChartMarket Cap Chart
Since November 8, 2017, InflaRx's market cap has decreased from $351.36M to $308.00M, a decrease of -12.34%. That is a compound annual growth rate of -1.48%.
| Date | Market Cap | % Change |
|---|---|---|
| Sep 11, 2026 | 308.00M | 350.13% |
| Dec 31, 2025 | 68.42M | -52.95% |
| Dec 31, 2024 | 145.44M | 51.53% |
| Dec 29, 2023 | 95.98M | -29.96% |
| Dec 30, 2022 | 137.03M | -34.85% |
| Dec 31, 2021 | 210.33M | 48.13% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Nov 8, 2017 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Q32 Bio | 319.13M |
| Upstream Bio | 314.93M |
| Abeona Therapeutics | 313.37M |
| SAB Biotherapeutics | 311.17M |
| Agenus | 310.19M |
| Vanda Pharmaceuticals | 304.73M |
| Lyell Immunopharma | 298.96M |
| Immuneering | 295.67M |